Cancer Res Treat.  2004 Jun;36(3):182-186.

Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study

• Ahn MJ
• Oh HS
• Choi JH
• Lee YY
• Kim IS
• Choi IY
• Lee OY
• Choi HS
• Kwon SJ

Abstract

PURPOSE
To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
MATERIALS AND METHODS
Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m(2) iv on day 1, heptaplatin 400 mg/m(2) iv on day 2 and 5-fluorouracil 800 mg/m(2) on day 2~4 were administered and the regimen was repeated every 3 weeks.
RESULTS
The median age of the patients was 60 years (range: 32~74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26~8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48~6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26~17.44). A median of 3 cycles (range: 1~7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life- threatening complication of pneumonia.
CONCLUSION
The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed.

Keyword

Gastric neoplasm; Combination chemotherapy; Heptaplatin; Paclifaxel; 5-fluorouracil

MeSH Terms

Aged
Anemia
Disease Progression
Drug Therapy, Combination*
Fluorouracil*
Follow-Up Studies
Humans
Liver
Lymph Nodes
Neoplasm Metastasis
Neutropenia
Paclitaxel*
Pilot Projects*
Pneumonia
Stomach Neoplasms*
Thrombocytopenia
Fluorouracil
Paclitaxel

Figure

• 

  Fig. 1 Time to progression in advanced gastric cancer patients.

• 

  Fig. 2 Overall survival in advanced gastric cancer patients.

Reference

1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Central Cancer Registry in Korea-2000: based on registered data from 131 hospitals. Cancer Res Treat. 2002; 34(2):77–83.

2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587–591. PMID: 7533517.

3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993; 72:37–41. PMID: 8508427.

4. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial of delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994; 5:189–190. PMID: 8186165.

5. In : Scheithauser W, Kome KG, Zeh B, editors. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. 1995. Second International Conference on Biology, Prevention and Treatment of GI Malignancy, Koln; Germany. 68 (Abstr).

6. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992; 10:541–548. PMID: 1548519.

7. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer cooperative group. J Clin Oncol. 2000; 18:2648–2657. PMID: 10894863.

8. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15:261–267. PMID: 8996151.

9. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71:3813–3818. PMID: 8508349.

10. Shimada Y, Shirao K, Ohtsu A. A phase III study of UFT+MMC versus 55-FU+CDPP versus 5-FU alone in patients with advanced gastric cancer; JCOG study 9205. Proc ASCO. 1999; 18:272a. (Abstr).

11. Kim HT, Kim DK, Cho YB, Kim TS, Jung IH, Kim KH, Heo DS, Bang YJ, Shin SW, Kim NK. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonate [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II). Cancer Chemother Pharmacol. 1998; 41:109–116. PMID: 9443623.

12. Kim DK, Kim HT, Tai JH, Cho YB, Kim TS, Kim KH, Park JG, Hong WS. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonate [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol. 1995; 35:1–6. PMID: 7497577.

13. Kim NK, Im SA, Kim DW, Lee MH, Jung CW, Cho EK, Lee JT, Ahn JS, Heo DS, Bang YJ. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer. 1999; 86:1109–1115. PMID: 10506693.

14. Kim NK, Bang Y, Heo DS, Kang Y, Kang WK, Kim H, Kim H, Kim JS, Kim HT, Roh JK. SKI 2053R and 5-fluorouracil (5-FU) in advanced gastric adenocarcinoma; phase II clinical trial. Proc AM Soc Clin Oncol. 2000; 19:323a. (Abstr. 1277).

15. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999; 22:580–586. PMID: 10597742.

16. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy in the treatment of advanced gastric carcinoma. Cancer. 1999; 85:295–301. PMID: 10023695.

17. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, FA and cisplatin in patients with advanced gastric cancer. Br J Cancer. 2000; 83:458–462. PMID: 10945491.

18. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23–30. PMID: 14665611.

19. Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim SY, Yoon HJ, Cho KS, Kim JS. Pilot study of heptoplatin, UFT-E, and leucovorin in advanced gastric carcinoma. Cancer Res Treat. 2003; 35(2):117–122.

20. Koizumi W, Taguchi T. A phase II study of capecitabine (Xeloda) in patients with advanced-metastatic gastric carcinoma. Proc Am Soc Clin Oncol. 2001; 20:142b. (Abstr. 2320).

21. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil in advanced gastric cancer. Oncology. 2000; 58:191–197. PMID: 10765119.